Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network

被引:36
|
作者
Wu, Li-Tzy [1 ,2 ]
Ling, Walter
Burchett, Bruce [1 ]
Blazer, Dan G. [1 ,2 ]
Shostak, Jack [2 ]
Woody, George E.
机构
[1] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC USA
[2] Duke Univ, Med Ctr, Durham, NC USA
来源
基金
美国国家卫生研究院;
关键词
buprenorphine; clinical trials network; gender differences; heath disparity; HIV risk behavior; methadone; opioid dependence; rehabilitation;
D O I
10.2147/SAR.S15151
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Purpose: Detoxification often serves as an initial contact for treatment and represents an opportunity for engaging patients in aftercare to prevent relapse. However, there is limited information concerning clinical profiles of individuals seeking detoxification, and the opportunity to engage patients in detoxification for aftercare often is missed. This study examined clinical profiles of a geographically diverse sample of opioid-dependent adults in detoxification to discern the treatment needs of a growing number of women and whites with opioid addiction and to inform interventions aimed at improving use of aftercare or rehabilitation. Methods: The sample included 343 opioid-dependent patients enrolled in two national multi-site studies of the National Drug Abuse Treatment Clinical Trials Network (CTN001-002). Patients were recruited from 12 addiction treatment programs across the nation. Gender and racial/ethnic differences in addiction severity, human immunodeficiency virus (HIV) risk, and quality of life were examined. Results: Women and whites were more likely than men and African Americans to have greater psychiatric and family/social relationship problems and report poorer health-related quality of life and functioning. Whites and Hispanics exhibited higher levels of total HIV risk scores and risky injection drug use scores than African Americans, and Hispanics showed a higher level of unprotected sexual behaviors than whites. African Americans were more likely than whites to use heroin and cocaine and to have more severe alcohol and employment problems. Conclusions: Women and whites show more psychopathology than men and African Americans. These results highlight the need to monitor an increased trend of opioid addiction among women and whites and to develop effective combined psychosocial and pharmacologic treatments to meet the diverse needs of the expanding opioid-abusing population. Elevated levels of HIV risk behaviors among Hispanics and whites also warrant more research to delineate mechanisms and to reduce their risky behaviors.
引用
收藏
页码:13 / 22
页数:10
相关论文
共 16 条
  • [1] Using a latent variable approach to inform gender and racial/ethnic differences in cocaine dependence: A National Drug Abuse Treatment Clinical Trials Network study
    Wu, Li-Tzy
    Pan, Jeng-Jong
    Blazer, Dan G.
    Tai, Betty
    Stitzer, Maxine L.
    Woody, George E.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2010, 38 (04) : S70 - S79
  • [2] Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study
    Weiss, Roger D.
    Potter, Jennifer Sharpe
    Griffin, Margaret L.
    Provost, Scott E.
    Fitzmaurice, Garrett M.
    McDermott, Katherine A.
    Srisarajivakul, Emily N.
    Dodd, Dorian R.
    Dreifuss, Jessica A.
    McHugh, R. Kathryn
    Carroll, Kathleen M.
    DRUG AND ALCOHOL DEPENDENCE, 2015, 150 : 112 - 119
  • [3] Long-term Outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study
    Weiss, Roger
    AMERICAN JOURNAL ON ADDICTIONS, 2016, 25 (04): : 325 - 325
  • [4] Racial and ethnic differences in asthma and mental health among US adults: results from the national survey on drug use and health
    Arias, Devin
    Becerra, Benjamin J.
    Becerra, Monideepa B.
    JOURNAL OF ASTHMA, 2015, 52 (07) : 715 - 720
  • [5] Opioid Use Disorder in Women: Evidence from the National Institute on Drug Abuse Clinical Trials Network (CTN) and the Implications for Treatment
    Greenfield, Shelly
    Rosa, Carmen
    Barbosa-Leiker, Celestina
    Campbell, Aimee
    McHugh, Kathryn
    Guille, Constance
    Ouseph, Rita
    Sise, Robert
    AMERICAN JOURNAL ON ADDICTIONS, 2019, 28 (03): : 162 - 162
  • [6] Personal and contextual factors in substance abuse treatment among racial and ethnic minorities: Studies from the NIDA clinical trials network FOREWORD
    Burlew, A. Kathleen
    Sanchez, Katherine
    JOURNAL OF ETHNICITY IN SUBSTANCE ABUSE, 2017, 16 (04) : 401 - 403
  • [7] Gender differences in attitudes toward AIDS clinical trials among urban HIV-infected individuals from racial and ethnic minority backgrounds
    Gwadz, M. V.
    Leonard, N. R.
    Nakagawa, A.
    Cylar, K.
    Finkelstein, M.
    Herzog, N.
    Tharaken, M.
    Mildvan, D.
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2006, 18 (07): : 786 - 794
  • [8] Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network
    Wu, Li-Tzy
    Ling, Walter
    Burchett, Bruce
    Blazer, Dan G.
    Yang, Chongming
    Pan, Jeng-Jong
    Reeve, Bryce B.
    Woody, George E.
    DRUG AND ALCOHOL DEPENDENCE, 2011, 118 (2-3) : 186 - 193
  • [9] Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network
    Wu, Li-Tzy
    John, William S.
    Ghitza, Udi E.
    Wahle, Aimee
    Matthews, Abigail G.
    Lewis, Mitra
    Hart, Brett
    Hubbard, Zach
    Bowlby, Lynn A.
    Greenblatt, Lawrence H.
    Mannelli, Paolo
    ADDICTION, 2021, 116 (07) : 1805 - 1816
  • [10] A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid, detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network
    Ling, W
    Amass, L
    Shoptaw, S
    Annon, JJ
    Hillhouse, M
    Babcock, D
    Brigham, G
    Harrer, J
    Reid, M
    Muir, J
    Buchan, B
    Orr, D
    Woody, G
    Krejci, J
    Ziedonis, D
    ADDICTION, 2005, 100 (08) : 1090 - 1100